1 week Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer TherapyZacks
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT’s lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
Biotech · China · Merck&Co (MRK)
X